Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.71+0.04 (+1.09%)
Close on Nov 13, 2026Market cap $240.27MP/E –Yield –
Immuneering gross margin
Gross margin is gross profit as a percentage of revenue.
Immuneering's gross margin for the twelve months ending Sep 30, 2023 was 100.0%. For fiscal 2022 it was 50.1%, against 44.6% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 50.1% | +5.5 |
| FY2021 | Dec 31, 2021 | 44.6% | −0.0 |
| FY2020 | Dec 31, 2020 | 44.6% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | 100.0% | +108.8 |
| Q3 FY2022 | Sep 30, 2022 | 49.6% | −5.0 |
| Q2 FY2022 | Jun 30, 2022 | 49.2% | −2.5 |
| Q1 FY2022 | Mar 31, 2022 | 50.5% | +5.2 |
| Q4 FY2021 | Dec 31, 2021 | -8.8% | −37.6 |
| Q3 FY2021 | Sep 30, 2021 | 54.6% | +0.7 |
| Q2 FY2021 | Jun 30, 2021 | 51.7% | +1.0 |
| Q1 FY2021 | Mar 31, 2021 | 45.3% | – |
| Q4 FY2020 | Dec 31, 2020 | 28.8% | – |
| Q3 FY2020 | Sep 30, 2020 | 53.9% | – |
| Q2 FY2020 | Jun 30, 2020 | 50.7% | – |
See a number that looks wrong?